Skip to main content
Fig. 4 | BMC Nephrology

Fig. 4

From: An open-label phase 2 trial to assess the efficacy, safety and pharmacokinetics of lanthanum carbonate in hyperphosphatemic children and adolescents with chronic kidney disease undergoing dialysis

Fig. 4

LC plasma concentrations for patients after a single oral dose (part 1, n = 20). Pharmacokinetic set 1 included all patients from safety analysis set 1 who had at least one measurable plasma concentration of LC post-dose. Patients with LC plasma concentrations below the lower limit of quantification (0.05 ng/mL) were not included at the respective time points; lower SD error bars have been omitted for clarity

LC lanthanum carbonate, SD standard deviation

Back to article page

BMC Nephrology

ISSN: 1471-2369

Contact us